Colorectal Cancer (CRC) Screening Tests - Coding Guide

Most of the patients believe that they are entitled to colorectal cancer screening coverage from their insurance plan. That assumption collapses the moment the bill is received.  Under updated federal guidelines, these screenings are now free to a broader patient population. But it is only possible when claims reflect the correct procedure codes, diagnosis codes, and modifiers. One documentation gap changes that outcome entirely.

The guideline includes a detailed coding guide for Colorectal Cancer Screening Tests to help providers and billing staff better understand these screening tests, the appropriate CPT and ICD-10 coding for these services, modifier use, and documentation requirements. It also provides guidance on how preventive screening claims should be reported to better reflect current federal coverage policies, and to minimize unanticipated patient billing.

Important: Rules for Medicaid vary by state. Commercial health plans in effect on or before March 23, 2010, and certain employer-sponsored health care plans are not required to follow the coverage mandates described below.

Screening Colonoscopy - No Polyps Removed

A screening colonoscopy with no polyps found or removed follows a straightforward coding path, but the rules differ between commercial insurance and Medicare. Using the wrong code set for the wrong payer is one of the most frequent sources of unnecessary patient billing in this category.

Commercial insurance

For patients with commercial insurance, CPT code 45378 (diagnostic colonoscopy) is typically reported when no therapeutic intervention is performed. In these cases, modifier 33 (Preventive Services) should generally be appended to indicate that the procedure was performed for screening purposes. Failure to apply this modifier correctly is a frequent cause of patients being incorrectly billed for preventive colonoscopy services.

Medicare

Coding for Medicare patients is done by screening eligibility and risk status. For average-risk people who are undergoing colorectal cancer screening, use G0121; for those who are at high risk, use G0105. 

ICD-10-CM Diagnosis Coding

Correct diagnosis coding is necessary for supporting medical necessity and screening purposes. Reporting screening colonoscopies on a Tear Sheet report should include the primary diagnosis of Z12.11 (Encounter for screening for malignant neoplasm of colon). 

Additional codes may be reported based on patient history, including:

• Z12.12 – Screening for malignant neoplasm of the rectum
• Z80.0 – Family history of malignant neoplasm of the digestive organs 
• Polyp(s) in the Colon, Family history of: (Z83.71)
• Z85.038 – The personal history of malignant neoplasm of the large intestines is classified in this category.Personal history of malignant neoplasm of large intestine is classified in this category.  
• Z85.048 – Personal history of malignant lesion of rectum, rectosigmoid junction, and anus
• Z86.010 – Personal history of colonic polyps

These secondary diagnoses help support screening eligibility and risk stratification when applicable.

Insurance Coverage Considerations

When preventive screening colonoscopy is performed with an appropriate diagnosis code and preventive modifier for commercial insurance plans, the screening should be performed without any patient cost sharing. Coverage may differ by individual plan design, by being deductible or not and by network agreements.

Medicare benefits are provided according to risk category for screening colonoscopy services. If there are no polyps and the colonoscopy is done as screening, the colonoscopy and colonoscopy anesthesia services may be covered by preventive benefits, as determined by Medicare benefit coverage and eligibility requirements. 

Patient Coverage

• Commercial Insurance: Colonoscopy, bowel preparation, sedation, lab fees and hospital or ambulatory surgery center fees are fully covered.
• Medicare: Colonoscopy and sedation 100% if no polyps are found. 

Screening Colonoscopy - With Polyp Removal

The procedure code should indicate the type of removal if a polyp or lesion is detected and removed during a screening colonoscopy. When various polyps or lesions are removed during the same procedure, a note for each method should be made. 

NOTE: Modifier 33 or PT must be added to identify the polypectomy as part of a preventive screening service. Without the correct modifier, the claim may be processed as a diagnostic procedure, resulting in patient cost-sharing.

Procedure Codes - Commercial Insurance & Medicare

• Colonoscopy, flexible with biopsy, single or multiple (45380) 
• 45384 - Colonoscopy it is flexible with removal of tumor(s), polyp or polyps, or other lesion(s) using hot biopsy forceps.
• 45385 - Colonoscopy with removal of lesion(s) (tumor(s), polyp(s)) by snare technique.
• Colonoscopy which is flexible (with ablation of tumor(s), polyp(s), or other lesion(s), including pre-dilation, post-dilation, and passage of guide wire if done) - 45388.

Modifiers

Modifier 33 (preventive services) - Add to commercial insurance claims to identify preventive service.

Modifier PT Code for Medicare if the procedure is a screening colonoscopy that is followed by the removal of the polyps. 

ICD-10-CM Diagnosis Codes

• Z12.11 - For malignant neoplasm of colon (list first when reporting multiple diagnoses) while screening
• Z12.12 - While screening for malignant neoplasm of rectum (first when reporting multiple diagnoses)
• D12.0 - Benign neoplasm of the cecum
• D12.4 - Benign neoplasm of descending colon
• D12.8 - Benign neoplasm of the rectum 

Insurance Coverage

Commercial insurance

Colonoscopy, bowel preparation, sedation, laboratory services, and facility costs are generally covered under preventive benefits when coded correctly.

Medicare

If done in the context of a screening and no complications other than removal of polyps, coverage would be based on Medicare preventive screening rules and may be subject to cost-sharing based on the type of services rendered. 

Stool-Based Screening Tests

Stool-based tests are a non-invasive first-line colorectal cancer screening option. When a stool-based test returns a positive result, a follow-up colonoscopy is required. Correct coding and modifier selection on that follow-up procedure is essential to ensure it is processed appropriately for billing and patient cost-sharing purposes.

NOTE: For commercial insurance, modifier 33 is typically appended to the screening colonoscopy CPT code following a positive stool-based test to indicate preventive intent. For Medicare, modifier KX is used when medical policy requirements for the screening service have been met. Incorrect or missing modifiers may result in the colonoscopy being processed as diagnostic.

Procedure Codes - Commercial Insurance

• 82274 - Fecal immunochemical test (qualitative), 1–3 samples
• The 82270 FOBT (guaiac-based) test is a qualitative consecutive specimen test.
• Multi-target stool DNA test (Cologuard-type assay with DNA markers and fecal hemoglobin) – 81528 

Procedure Codes - Medicare

• G0328 - FIT (fecal immunochemical test for colorectal cancer screening)
• 82270 - FOBT (same definition as commercial use)
• 81528 - Multi-target stool DNA test

Modifiers for Follow-Up Colonoscopy

• Modifier 33 - Used for commercial insurance screening colonoscopy following a positive stool-based test to indicate preventive service status.
• Modifier KX - Used for Medicare screening colonoscopy when documentation confirms that medical policy requirements have been met following a positive stool-based test.

ICD-10-CM Diagnosis Codes

• Z12.10 - For malignant neoplasm of intestinal tract, unspecified durin screening
• Z12.11 - Screening for malignant neoplasm of colon
• Z12.12 - while screening for malignant neoplasm of rectum

Insurance Coverage Considerations

Stool-based screening is usually covered under commercial insurance and may be covered under follow-up colonoscopy if done as a result of a positive stool-based screening test (depending on plan rules and preventive service rules apply). 

Generally, Medicare will pay for an approved stool-based screening test and follow-up screening colonoscopy services, following preventive screening guidelines. Depending on the findings (e.g., polyp removal or diagnosis to diagnostics) patient cost sharing may still be applicable. 

What to Do When a Patient Receives an Unexpected Bill

Even when correct coding is applied, some claims may still be denied or result in unexpected patient cost-sharing. The following steps address the two most common colorectal cancer screening billing issues.

Colonoscopy Following a Positive Stool-Based Test

• Make sure the correct modifier was applied.
• Use modifier 33 with the appropriate colonoscopy CPT code for patients with commercial insurance.
• Use modifier KX with HCPCS codes G0105 or G0121 for Medicare when polyps are not removed. If polyps are removed, Medicare considers the colonoscopy diagnostic, and coinsurance will apply.
• Ask the patient whether their insurance plan was established on or before March 23, 2010, or whether it is an employer-sponsored health plan. These plans are not required to provide all Affordable Care Act preventive coverage requirements and may not be obligated to cover a colonoscopy following a positive stool-based test.
• Contact the insurance carrier and request clarification on the reason for denial or patient billing.

Screening Colonoscopy When a Polyp Was Removed

• Ensure modifier 33 was correctly appended to the colonoscopy CPT code for commercial insurance patients.
• Confirm whether the patient’s plan falls under ACA-exempt categories, such as pre–March 23, 2010 plans or certain employer-sponsored plans.
• Contact the insurer to determine the reason for the denial or the status of the cost-sharing application.

BillingFreedom: 98.7% Accuracy Driving 15–22% Revenue Growth in Gastroenterology Billing 

BillingFreedom's certified gastroenterology medical billing experts possess extensive, current knowledge of all CRC screening and follow-up situations, such as stool-based testing scenarios, screening colonoscopies, and coding differences associated with polypectomy.

Our teams are trained in payer-specific differentiation between commercial insurance and Medicare, including the proper use of CPT, HCPCS, and ICD-10-CM code sets such as 45378, G0121, G0105, and 81528. We also ensure strict adherence to modifier rules, recognizing that modifier PT applies exclusively to Medicare conversions, while modifier 33 is required for commercial preventive services.

Performance Metrics That Drive Revenue Growth

BillingFreedom's gastroenterology billing operations run on measurable benchmarks. Not general targets. Actual numbers that reflect what happens to claims in the real world.

Our results:

• Coding accuracy holds at 98.7%
• First-pass acceptance at 96.4%
• Denial rate stays under 1%
• Net collections have increased up to 15–22% for practices that made the switch

Structured Dispute Resolution and Revenue Protection

BillingFreedom has developed a structured resolution process that seeks to address not only the surface issue, but also the root cause of unexpected patient billing and claim denials. The analysis of each case is conducted to see if the problem is due to modifier omissions, coding errors, payer interpretation, or plan specific exemptions.

Our staff relying on supplemental regulatory references, such as the U.S. Department of Labor (DOL) and the Department of Health and Human Services (HHS) when applicable, to guide coverage of preventive services coverage. This will make sure that appeals are both correct and backed up by authority standards of compliance. 

To find out more information about our superior medical billing services, do not hesitate to write us an email at info@billingfreedom.com or call us at +1 (855) 415-3472. 

We are concerned about your financial peace!